Record linkage for pharmacoepidemiological studies in cancer patients

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 94-103

  Van Herk Sukel, Myrthe P P ^a   Lemmens, Valery E P P ^b,c   Van De Poll Franse, Lonneke V ^b,d   Herings, Ron M C ^a,c   Coebergh, Jan Willem W ^b,c  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d TILBURG UNIVERSITY   (Netherlands)

Author keywords

Cancer registry; Comorbidity; Databases; Drug utilization; Linkage; Post approval surveillance

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EUROPE; HEALTH CARE UTILIZATION; HUMAN; LONGITUDINAL STUDY; NEOPLASM; NORTH AMERICA; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; EUROPE; HUMANS; MEDICAL RECORD LINKAGE; NEOPLASMS; NORTH AMERICA; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY; REGISTRIES;

EID: 84855342798     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2205     Document Type: Review

References (61)

1. Johnson KA, Brown PH. Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol 2010; 37: 345-358.
2. Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003; 21: 3859-3866.
3. Viale PH, Moore S. Postmarketing surveillance for oncology drugs. Clin J Oncol Nurs 2008; 12: 877-886.
4. [12 July 2010].
5. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-748.
6. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18.
7. [9 September 2010].
8. [9 September 2010].
9. Anderson RT, Camacho FT, Balkrishnan R, et al. Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid insurance. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005; 23(16S, part I of II, June 1 suppl): 6021 (abstract).
10. Schrag D, Virnig BA, Warren JL. Linking tumor registry and Medicaid claims to evaluate cancer care delivery. Health Care Financ Rev 2009; 30: 61-73.
11. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 2002; 94: 490-496.
12. [August 2010].
13. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
14. [16 August 2010].
15. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. In Pharmacoepidemiology (3rd edn), Strom BL (ed.). Wiley: Chichester, 2000; 325-345.
16. Tamim HM, Tagalakis V. Validating a method that deals with missing drug information in the Saskatchewan Drug Plan database. Pharmacoepidemiol Drug Saf 2009; 18: 140-146.
17. Manitoba Centre for Health Policy. [18 September 2010].
18. [18 September 2010].
19. Roos LL, Mustard CA, Nicol JP, et al. Registries and administrative data: organization and accuracy. Med Care 1993; 31: 201-212.
20. Miller E, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. CMAJ 1996; 154: 1855-1864.
21. Tricco AC, Pham B, Rawson NS. Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. J Clin Epidemiol 2008; 61: 192-197.
22. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008; 18: 129-136.
23. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-1231.
24. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48: 27-33.
25. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
26. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage--record linkage study. Int J Cancer 2010; 126: 279-284.
27. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-369.
28. Hallas J. Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 2001; 10: 619-623.
29. Jarlbaek L, Andersen M, Kragstrup J, Hallas J. Cancer patients' share in a population's use of opioids. A linkage study between a prescription database and the Danish Cancer Registry. J Pain Symptom Manage 2004; 27: 36-43.
30. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002; 11: 359-364.
31. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry--history, content, quality and use. Dan Med Bull 1997; 44: 535-539.
32. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
33. [12 July 2010].
34. Evans JM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999; 47: 105-110.
35. [12 July 2010].
36. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010; 46: 395-404.
37. Geiger AM, Buist DS, Greene SM, Altschuler A, Field TS. Survivorship research based in integrated healthcare delivery systems: the Cancer Research Network. Cancer 2008; 112: 2617-2626.
38. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 2005; 35: 3-11.
39. [23 September 2010].
40. Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr 2005; 35: 12-25.
41. Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW. Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10years older without cardiovascular morbidity. Crit Rev Oncol Hematol 2010; 76(3): 196-207.
42. Ernst MF, Voogd AC, Coebergh JW, Poortmans PM, Roukema JA. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment. Eur J Cancer 2004; 40: 487-493.
43. Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28: 2423-2429.
44. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care 2002; 40: IV-75-81.
45. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2009; 106: 86-94.
46. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99: 1763-1768.
47. Aiello Bowles EJ, Tuzzio L, Ritzwoller DP, et al. Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research. Med Care 2009; 47: 1091-1097.
48. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002; 40: IV-55-61.
49. Pascoe SW, Neal RD, Heywood PL, Allgar VL, Miles JN, Stefoski-Mikeljevic J. Identifying patients with a cancer diagnosis using general practice medical records and Cancer Registry data. Fam Pract 2008; 25: 215-220.
50. Tamim HM, Hajeer AH, Boivin JF, Collet JP. Association between antibiotic use and risk of prostate cancer. Int J Cancer 2010; 127: 952-960.
51. [16 August 2010].
52. Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004; 94: 540-549.
53. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009; 27: 3445-3451.
54. Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5years of tamoxifen. Ann Oncol 2007; 18: 45-51.
55. Tamim HM, Hanley JA, Hajeer AH, Boivin JF, Collet JP. Risk of breast cancer in relation to antibiotic use. Pharmacoepidemiol Drug Saf 2008; 17: 144-150.
56. Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007 - pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010; 14: 289-294.
57. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754.
58. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer 2010; 126: 285-296.
59. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 2000; 89: 165-170.
60. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625.
61. Sukel MP, Breekveldt-Postma NS, Erkens JA, et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf 2008; 17: 125-134.